aztreonam has been researched along with Disease Exacerbation in 4 studies
Aztreonam: A monocyclic beta-lactam antibiotic originally isolated from Chromobacterium violaceum. It is resistant to beta-lactamases and is used in gram-negative infections, especially of the meninges, bladder, and kidneys. It may cause a superinfection with gram-positive organisms.
aztreonam : A synthetic monocyclic beta-lactam antibiotic (monobactam), used primarily to treat infections caused by Gram-negative bacteria. It inhibits mucopeptide synthesis in the bacterial cell wall, thereby blocking peptidoglycan crosslinking.
| Excerpt | Relevance | Reference |
|---|---|---|
| " The current dosing recommendations in the United States and Europe for aztreonam are lower than the literature supported dosing range of 200-300 mg/kg/day divided every 6 hr, maximum 8-12 g/day." | 6.48 | Optimization of anti-pseudomonal antibiotics for cystic fibrosis pulmonary exacerbations: I. aztreonam and carbapenems. ( Ampofo, K; Sherwin, CM; Spigarelli, MG; Stockmann, C; Waters, CD; Young, DC; Zobell, JT, 2012) |
| " The current dosing recommendations in the United States and Europe for aztreonam are lower than the literature supported dosing range of 200-300 mg/kg/day divided every 6 hr, maximum 8-12 g/day." | 2.48 | Optimization of anti-pseudomonal antibiotics for cystic fibrosis pulmonary exacerbations: I. aztreonam and carbapenems. ( Ampofo, K; Sherwin, CM; Spigarelli, MG; Stockmann, C; Waters, CD; Young, DC; Zobell, JT, 2012) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 4 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Tiddens, HA | 2 |
| Bos, AC | 1 |
| Mouton, JW | 1 |
| Devadason, S | 1 |
| Janssens, HM | 1 |
| Fjaellegaard, K | 1 |
| Sin, MD | 1 |
| Browatzki, A | 1 |
| Ulrik, CS | 1 |
| Littlewood, KJ | 1 |
| Higashi, K | 1 |
| Jansen, JP | 1 |
| Capkun-Niggli, G | 1 |
| Balp, MM | 1 |
| Doering, G | 1 |
| Angyalosi, G | 1 |
| Zobell, JT | 1 |
| Young, DC | 1 |
| Waters, CD | 1 |
| Stockmann, C | 1 |
| Ampofo, K | 1 |
| Sherwin, CM | 1 |
| Spigarelli, MG | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Effect of Roflumilast on Quality of Life, Lung Function and Mucus Properties in Patients With Non-cystic Fibrosis Bronchiectasis: a Cross-over, Unicentric, Double-blind and Placebo-controlled Study[NCT03988816] | Phase 2 | 30 participants (Anticipated) | Interventional | 2019-12-06 | Recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
4 reviews available for aztreonam and Disease Exacerbation
| Article | Year |
|---|---|
Inhaled antibiotics: dry or wet?
Topics: Administration, Inhalation; Aerosols; Anti-Bacterial Agents; Aztreonam; Colistin; Cystic Fibrosis; D | 2014 |
Antibiotic therapy for stable non-CF bronchiectasis in adults - A systematic review.
Topics: Aminoglycosides; Anti-Bacterial Agents; Aztreonam; Bronchiectasis; Ciprofloxacin; Colistin; Disease | 2017 |
A network meta-analysis of the efficacy of inhaled antibiotics for chronic Pseudomonas infections in cystic fibrosis.
Topics: Administration, Inhalation; Adolescent; Adult; Anti-Bacterial Agents; Aztreonam; Bacterial Load; Bay | 2012 |
Optimization of anti-pseudomonal antibiotics for cystic fibrosis pulmonary exacerbations: I. aztreonam and carbapenems.
Topics: Anti-Bacterial Agents; Aztreonam; Carbapenems; Cystic Fibrosis; Disease Progression; Humans; Pseudom | 2012 |